1a- (4- (3- hydroxy- 1,3,5(10)- estratrien- 17- yloxycarbonyl)butyryl)mitomycin C
structure in first source
Networked: 4
relevant articles (1 outcomes,
0 trials/studies)
Relationship Network
Bio-Agent Context: Research Results
Experts
Related Diseases
1. | Sarcoma 180
|
2. | Neoplasms (Cancer)
11/01/1998
- " EB-glu-MMC and E-glu-MMC were demonstrated to produce prolonged retention, to enter the systemic circulation to a fair extent, and to exhibit a good effect against the general solid tumor, Sarcoma 180, in vivo." 10/01/1997
- " E-glu-MMC is considered to be an effective antitumor agent which gradually generates MMC in the body, and its receptor-mediated action to target cells such as estrogen receptor-positive tumor cells might be possible." 07/26/2004
- " In the suspension dosage forms, these conjugates had a greater suppressive effect on tumor growth at 50 mg MMC eq./kg than MMC at 5 mg/kg, and reduced the body weight and leukocyte number, with E-glu-MMC more toxic than EB-glu-MMC. " 11/01/1998
- " Conjugates of mitomycin C (MMC) with estradiol benzoate and estradiol via glutaric acid, abbreviated to EB-glu-MMC and E-glu-MMC, respectively, as previously reported, were examined concerning their pharmacokinetic behaviors and antitumor effects against two kinds of general and popular tumors, P388 leukemia and Sarcoma 180. "
|
3. | Leukemia P388
|
4. | Body Weight (Weight, Body)
|
|
Related Drugs and Biologics